In 2016, Spinraza® became a game-changer for spinal muscular atrophy (SMA) patients. It was the first FDA-approved treatment for the neurodegenerative disease, which is the leading genetic cause of infant death.
One way to improve the effect of a drug is by increasing its dosage. But as with any drug, increasing the amount of Spinraza® also increases the risk of toxic side effects. The authors took a different approach. They discovered that pairing Spinraza® with valproic acid (VPA) may be an alternate way to improve its clinical effect without using more of the drug.
The senior author explains: “Sometimes you don’t want to use a ton of a drug. If you have a condition that allows you to use less drug, then you may have fewer toxicities. So the idea is to combine these two drugs to get maximal effects.”
People with SMA don’t have enough of a protein called SMN. Spinraza® is a type of molecule called an antisense oligonucleotide (ASO) that helps cells make more SMN protein from a gene called SMN2. The team discovered that there were roadblocks on the SMN2 gene when using Spinraza®. This slowed down the cellular machine producing SMN protein. The drug VPA helps remove the roadblocks, allowing Spinraza® to further increase the SMN protein output.
When mice with SMA were treated with both VPA and a Spinraza®-like ASO used for research, the mice survived longer and had improved muscle function.
Over 11,000 SMA patients have been treated with Spinraza® in more than 50 countries.
https://www.cell.com/cell/fulltext/S0092-8674(22)00529-3
Improving the therapeutic efficacy of spinal muscular atrophy drug!
- 846 views
- Added
Edited
Latest News
Protein found in brain link…
By newseditor
Posted 09 Dec
Calcium acts as missing lin…
By newseditor
Posted 09 Dec
How repeated traumatic brai…
By newseditor
Posted 08 Dec
Metformin rescues neuronal…
By newseditor
Posted 08 Dec
Variants in the genome inte…
By newseditor
Posted 08 Dec
Other Top Stories
Transformative treatment for HER2-positive gastric cancer
Read more
New biosensors measure toxic drugs in cancer, arthritis, and organ…
Read more
Copper and breast cancer!
Read more
Role of shared cancer gene network in malignancy
Read more
Chemotherapy-induced sensorimotor deficits
Read more
Protocols
Brain-wide circuit-specific…
By newseditor
Posted 05 Dec
Cheap, cost-effective, and…
By newseditor
Posted 03 Dec
Temporally multiplexed imag…
By newseditor
Posted 02 Dec
Efficient elimination of ME…
By newseditor
Posted 01 Dec
Personalized drug screening…
By newseditor
Posted 30 Nov
Publications
Extracellular calcium funct…
By newseditor
Posted 09 Dec
TAF15 amyloid filaments in…
By newseditor
Posted 09 Dec
Metformin rescues migratory…
By newseditor
Posted 08 Dec
Oral magnesium prevents ace…
By newseditor
Posted 08 Dec
GDF15 is a major determinan…
By newseditor
Posted 08 Dec
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar